Safety
angioedema, renal dysfunction, hyperkalemia, hypotension
ANGIOEDEMA
When measuring the safety of the drug in the participants, four clinical parameters were taken into consideration i.e., the occurrence of either hypotension, hyperkalemia, renal dysfunction, or angioedema among the participants. During the study duration of 12 weeks, hyperkalemia remains the main safety concern with incidence rate of 21.3% (23) followed by hypotension in 19.4% (21), and renal dysfunction in 3.7% (4) of the patients. However, none of the patient developed angioedema during this study. When assessed for various baseline characteristics, the incidence rate of hypotension was significantly higher (